Nature says a personalized treatment based on messenger RNA has unveiled good first results. Half of the 16 participants developed cells that could spot cancer cells and prevent them from coming back.
The trial focused on pancreatic ductal adenocarcinoma (PDAC), which accounts for more than 90% of pancreatic cancer cases. Only about 10% of PDAC patients are alive within two years of diagnosis, according to the scientific journal.. The results reinforce the idea already well present in the medical community that messenger RNA, used for Covid-19 vaccines, has great potential.